Poseida Therapeutics Inc (PSTX)
2.73
+0.02
(+0.74%)
USD |
NASDAQ |
Nov 22, 16:00
2.86
+0.13
(+4.76%)
After-Hours: 20:00
Poseida Therapeutics Enterprise Value: 94.14M for Nov. 22, 2024
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 22, 2024 | 94.14M |
| November 21, 2024 | 92.19M |
| November 20, 2024 | 93.16M |
| November 19, 2024 | 98.03M |
| November 18, 2024 | 88.29M |
| November 15, 2024 | 97.06M |
| November 14, 2024 | 140.92M |
| November 13, 2024 | 147.74M |
| November 12, 2024 | 187.70M |
| November 11, 2024 | 189.65M |
| November 08, 2024 | 128.25M |
| November 07, 2024 | 113.63M |
| November 06, 2024 | 99.01M |
| November 05, 2024 | 87.31M |
| November 04, 2024 | 74.64M |
| November 01, 2024 | 68.79M |
| October 31, 2024 | 58.92M |
| October 30, 2024 | 59.90M |
| October 29, 2024 | 66.71M |
| October 28, 2024 | 69.64M |
| October 25, 2024 | 62.82M |
| October 24, 2024 | 63.79M |
| October 23, 2024 | 71.58M |
| October 22, 2024 | 71.58M |
| October 21, 2024 | 71.58M |
| Date | Value |
|---|---|
| October 18, 2024 | 66.71M |
| October 17, 2024 | 75.48M |
| October 16, 2024 | 75.48M |
| October 15, 2024 | 75.48M |
| October 14, 2024 | 71.58M |
| October 11, 2024 | 72.56M |
| October 10, 2024 | 68.66M |
| October 09, 2024 | 77.43M |
| October 08, 2024 | 78.40M |
| October 07, 2024 | 87.17M |
| October 04, 2024 | 82.30M |
| October 03, 2024 | 75.48M |
| October 02, 2024 | 85.22M |
| October 01, 2024 | 95.94M |
| September 30, 2024 | 106.65M |
| September 27, 2024 | 102.67M |
| September 26, 2024 | 109.47M |
| September 25, 2024 | 112.39M |
| September 24, 2024 | 120.16M |
| September 23, 2024 | 121.13M |
| September 20, 2024 | 148.33M |
| September 19, 2024 | 171.64M |
| September 18, 2024 | 161.92M |
| September 17, 2024 | 149.30M |
| September 16, 2024 | 112.39M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
-44.83M
Minimum
Jun 29 2023
866.37M
Maximum
Jul 20 2020
198.58M
Average
159.01M
Median
Mar 14 2024
Enterprise Value Benchmarks
| Organogenesis Holdings Inc | 504.71M |
| MaxCyte Inc | 220.63M |
| NovaBay Pharmaceuticals Inc | 2.608M |
| Palatin Technologies Inc | 16.38M |
| iBio Inc | 14.05M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 20.24M |
| Revenue (Quarterly) | 71.75M |
| Total Expenses (Quarterly) | 52.01M |
| EPS Diluted (Quarterly) | 0.21 |
| Profit Margin (Quarterly) | 28.20% |
| Earnings Yield | -22.71% |
| Normalized Earnings Yield | -22.71 |